Georgetown University Medical Center researchers discovered that Enada NADH, a naturally occurring coenzyme, can help alleviate some of the symptoms of Chronic Fatigue Syndrome (CFIDS/CFS) as an adjunctive therapy. The complete scientific study is published in the Annals of Allergy, Asthma & Immunology
The double-blind study conducted at Georgetown University Medical Center found that 31 percent of the patients who took ENADA, a stabilized form of the coenzyme NADH, as a nutritional supplement, achieved improved energy levels and mental alertness, compared to only 8 percent of the subjects who took a placebo. Subjects who received ENADA NADH took 10 mg per day.
In a follow-up study, 72 percent of patients saw marked improvement over time. Researchers identified no adverse effects from taking ENADA NADH and no interactions were reported with antidepressants or antihistamines.
NADH occurs in all living cells and plays a central role in the body's energy-producing capacity. NADH's primary responsibility is in the production of human cellular energy - Adenine Triphosphate (ATP). ATP is the cellular "spark" that provides energy from the cell's powerhouse organelle, the mitochondria.
Chronic Fatigue Syndrome is a debilitating disorder with no known cause or cure. More than 600,000 people are afflicted with the disease, and more than 2 million people believe they suffer from chronic fatigue. The primary symptom of CFS/CFIDS is severe, prolonged fatigue.
To read the published study abstract, click here